Shijiazhuang Yiling Pharmaceutical Co Ltd (002603) - Total Liabilities
Based on the latest financial reports, Shijiazhuang Yiling Pharmaceutical Co Ltd (002603) has total liabilities worth CN¥2.79 Billion CNY (≈ $407.83 Million USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore 002603 long-term investment intensity to see how much of total assets are deployed in long-term investments.
Shijiazhuang Yiling Pharmaceutical Co Ltd - Total Liabilities Trend (2008–2025)
This chart illustrates how Shijiazhuang Yiling Pharmaceutical Co Ltd's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see 002603 asset base.
Shijiazhuang Yiling Pharmaceutical Co Ltd Competitors by Total Liabilities
The table below lists competitors of Shijiazhuang Yiling Pharmaceutical Co Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Hiwin Technologies Corp
TW:2049
|
Taiwan | NT$17.79 Billion |
|
Bethel Automotive Safety Systems Co Ltd Class A
SHG:603596
|
China | CN¥8.67 Billion |
|
Planet Fitness Inc
NYSE:PLNT
|
USA | $3.62 Billion |
|
Arcadis N.V.
AS:ARCAD
|
Netherlands | €2.79 Billion |
|
Hangzhou Hangyang Co Ltd
SHE:002430
|
China | CN¥14.46 Billion |
|
Guangzhou Haige Communications Group Incorporated Co
SHE:002465
|
China | CN¥9.52 Billion |
|
Siegfried Holding Ltd
SW:SFZN
|
Switzerland | CHF949.22 Million |
|
Genworth Financial Inc
NYSE:GNW
|
USA | $77.60 Billion |
Liability Composition Analysis (2008–2025)
This chart breaks down Shijiazhuang Yiling Pharmaceutical Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See Shijiazhuang Yiling Pharmaceutical Co Lt net asset quality index to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.50 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.24 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.20 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Shijiazhuang Yiling Pharmaceutical Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Shijiazhuang Yiling Pharmaceutical Co Ltd (2008–2025)
The table below shows the annual total liabilities of Shijiazhuang Yiling Pharmaceutical Co Ltd from 2008 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | CN¥2.69 Billion ≈ $394.09 Million |
-13.60% |
| 2024-12-31 | CN¥3.12 Billion ≈ $456.13 Million |
-43.75% |
| 2023-12-31 | CN¥5.54 Billion ≈ $810.87 Million |
+2.42% |
| 2022-12-31 | CN¥5.41 Billion ≈ $791.73 Million |
+41.17% |
| 2021-12-31 | CN¥3.83 Billion ≈ $560.84 Million |
+48.28% |
| 2020-12-31 | CN¥2.58 Billion ≈ $378.24 Million |
+131.44% |
| 2019-12-31 | CN¥1.12 Billion ≈ $163.43 Million |
+12.41% |
| 2018-12-31 | CN¥993.56 Million ≈ $145.39 Million |
+28.11% |
| 2017-12-31 | CN¥775.58 Million ≈ $113.49 Million |
-16.16% |
| 2016-12-31 | CN¥925.04 Million ≈ $135.36 Million |
+5.17% |
| 2015-12-31 | CN¥879.56 Million ≈ $128.71 Million |
+31.04% |
| 2014-12-31 | CN¥671.19 Million ≈ $98.22 Million |
+67.93% |
| 2013-12-31 | CN¥399.69 Million ≈ $58.49 Million |
+24.61% |
| 2012-12-31 | CN¥320.75 Million ≈ $46.94 Million |
-38.76% |
| 2011-12-31 | CN¥523.78 Million ≈ $76.64 Million |
-22.98% |
| 2010-12-31 | CN¥680.08 Million ≈ $99.52 Million |
-5.40% |
| 2009-12-31 | CN¥718.89 Million ≈ $105.20 Million |
+106.65% |
| 2008-12-31 | CN¥347.88 Million ≈ $50.91 Million |
-- |
About Shijiazhuang Yiling Pharmaceutical Co Ltd
Shijiazhuang Yiling Pharmaceutical Co., Ltd. engages in the research and development, production, and sale of traditional Chinese medicine in China and internationally. It offers dietary supplements, and healthy food and drinks; patent TCM products for respiratory health, cardiovascular disease, diabetes, mellitus, oncology, urologic disease, sleep-improving, and anti-aging; disinfection and pers… Read more